Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan D Michelson

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
American Heart Journal|May 28, 2019
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)Liza Miriam Pina, Xiangwen Dong, Liping Zhang, et al.
Acta Haematologica|June 12, 2013
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot studyHung Chang, Lee-Yung Shih, Alan D Michelson, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
European Heart Journal|January 22, 2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J Angiolillo, Juan Jose Badimon, Jorge F Saucedo, et al.
Thrombosis and Haemostasis|September 10, 2021
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher DiseaseShoshana Revel-Vilk, Mira Naamad, Dafna Frydman, et al.
Infection and Immunity|October 1, 2008
Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin releaseDarin A Trier, Kimberly D Gank, Deborah Kupferwasser, et al.
American Heart Journal|March 30, 2002
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapyGuy L Wheeler, Gregory A Braden, Steven R Steinhubl, et al.
Plos One|August 25, 2016
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich PlasmaAndrew L Frelinger, Anja J Gerrits, Allen L Garner, et al.
Thrombosis and Haemostasis|June 30, 2011
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44Andrew L Frelinger, Alan D Michelson, Stephen D Wiviott, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
American Heart Journal|May 28, 2019
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)Liza Miriam Pina, Xiangwen Dong, Liping Zhang, et al.
Acta Haematologica|June 12, 2013
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot studyHung Chang, Lee-Yung Shih, Alan D Michelson, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
European Heart Journal|January 22, 2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J Angiolillo, Juan Jose Badimon, Jorge F Saucedo, et al.
Thrombosis and Haemostasis|September 10, 2021
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher DiseaseShoshana Revel-Vilk, Mira Naamad, Dafna Frydman, et al.
Infection and Immunity|October 1, 2008
Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin releaseDarin A Trier, Kimberly D Gank, Deborah Kupferwasser, et al.
American Heart Journal|March 30, 2002
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapyGuy L Wheeler, Gregory A Braden, Steven R Steinhubl, et al.
Plos One|August 25, 2016
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich PlasmaAndrew L Frelinger, Anja J Gerrits, Allen L Garner, et al.
Thrombosis and Haemostasis|June 30, 2011
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44Andrew L Frelinger, Alan D Michelson, Stephen D Wiviott, et al.
Pageof 13